Skip to main content
SGRY
NASDAQ Industrial Applications And Services

Surgery Partners Q2 Revenue Climbs 2.7%, Net Loss Deepens; $795M Hospital Sale Announced

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$15.95
Mkt Cap
$2.086B
52W Low
$11.41
52W High
$24.1
52W Position info
40% above low
Off High info
34% below high
Rel. Volume info
2.7× avg
Market data snapshot near publication time

SGRY sits 40% above its 52-week low of $11.41 on elevated volume (2.7× avg).

Summary

Surgery Partners reported mixed Q2 2026 results with revenue growth but widening losses, and separately announced a $795 million hospital sale that could transform its financial position.


Key Events · Earnings and Guidance · SGRY

  • Q2 Revenue Up, Losses Widen

    Revenue rose 2.7% to $848.9M, but net loss attributable to Surgery Partners grew to $15.0M from $2.5M a year ago. Adjusted EBITDA fell 2.9% to $125.2M.

  • $795M Hospital Sale Announced

    Subsequent to quarter-end, the company entered definitive agreements to sell two hospitals for total consideration of approximately $795 million, including proportionate debt. Proceeds are subject to adjustments and closing conditions.

  • Share Repurchase Authorization

    Board authorized a $200M share repurchase program in February 2026, but no shares were repurchased during Q2.

  • Valuation Allowance on Deferred Tax Assets

    Full valuation allowance recorded against net deferred tax assets due to a cumulative three-year pre-tax loss position, signaling uncertainty around future taxable income.


Analysis · SGRY · Industrial Applications And Services

Surgery Partners posted Q2 revenue of $848.9 million, a 2.7% increase year-over-year, but net loss attributable to the company widened to $15.0 million from $2.5 million a year ago. Adjusted EBITDA slipped 2.9% to $125.2 million. The quarter's results were overshadowed by a subsequent event: a definitive agreement to sell two hospitals for approximately $795 million in total consideration, a significant portfolio move that could reshape the balance sheet. The company also disclosed a $200 million share repurchase authorization, though no buybacks occurred in Q2. A full valuation allowance on deferred tax assets reflects persistent pre-tax losses, a red flag for future earnings power.

At the time of this filing, SGRY was trading at $15.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $11.41 to $24.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SGRY - Latest Insights

SGRY
Jul 24, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.70
Real-time Price: $15.95 info
Change: +$0.250 (+2%) info
Market Cap: $2.086B info
SGRY
May 05, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.45
Real-time Price: $15.95 info
Change: +$1.50 (+10%) info
Market Cap: $2.086B info
SGRY
May 05, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.45
Real-time Price: $15.95 info
Change: +$1.50 (+10%) info
Market Cap: $2.086B info
SGRY
Mar 02, 2026, 5:15 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $12.20
Real-time Price: $15.95 info
Change: +$3.75 (+31%) info
Market Cap: $2.086B info
SGRY
Mar 02, 2026, 5:11 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $12.29
Real-time Price: $15.95 info
Change: +$3.66 (+30%) info
Market Cap: $2.086B info